RECRUITINGINTERVENTIONAL
Efficacy and Safety of Etrasimod in Elderly Patients With Ulcerative Colitis
A Prospective Study on the Efficacy and Safety of a Novel Oral Drug, Etrasimod, in Elderly Patients With Ulcerative Colitis
About This Trial
Eligible patients will be identified in regular clinical practice. After providing thorough explanation and obtaining voluntary written informed consent, the clinical course, adverse events, endoscopic findings, and histopathological changes in biopsy specimens after Etrasimod administration will be prospectively collected and analyzed.
Who May Be Eligible (Plain English)
Who May Qualify:
- Patients with active ulcerative colitis
Who Should NOT Join This Trial:
- the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune conditions (where your immune system attacks your own body), and infectious disease
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Patients with active ulcerative colitis
Exclusion Criteria:
* the presence of acute or chronic renal failure, chronic heart disease, pulmonary infection, liver cirrhosis, colorectal cancer, autoimmune disease, and infectious disease
Treatments Being Tested
DRUG
Etrasimod administration
2 mg of Etrasimod is orally administered everyday.
Locations (1)
Showa Inan General Hospital
Komagane, Nagano, Japan